2023-10-24T13:00:43-05:00 2022-12-31 WITHUMSMITHBROWNPC 4600 EAST WEST HWY 900 BETHESDA MD 208143423 990 2022-01-01 042531031 NATIONAL FOUNDATION FOR CANCER RESEARCH % KWOK LEUNG NATI 3016541250 5515 SECURITY LANE Suite 1105 ROCKVILLE MD 20852 SUJUAN BA PRESIDENT & CEO 3016541250 2023-10-04 true SUJUAN BA 999009999 RICHARD RUVELSON P00234075 3012726000 2 2022 2023-04-26 12:10:37Z SUJUAN BA 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 8866070 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 6 6 16 50 0 0 9444496 8181991 0 0 464445 138215 172312 87853 10081253 8408059 4293164 2285179 0 0 2089022 2194753 31140 31557 1588576 3781181 3973419 10194507 8484908 -113254 -76849 12143234 10719078 2919358 3111496 9223876 7607582 X SEE SCHEDULE O false false 3841341 2285179 CANCER RESEARCH - SEE SCHEDULE O 2297991 CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O 6139332 true true false false false true false false false true true false false true true true false true false false true false true true true false false true true true false false false false false false false false true false false false false true true false false false true 25 0 true 16 true false false false false false true true false false false false false false false false false X 6 6 false false false false true false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X KWOK LEUNG 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 X SUJUAN BA PRESIDENT/CEO 40.0 1.0 X 427108 0 84633 YI WANG CHIEF STRTGY OFF(THRU 08/2022) 40.0 0.0 X 247490 0 18755 KWOK LEUNG CFO/SECRETARY 40.0 5.0 X 195021 0 28926 BRIAN WACHTEL EXECUTIVE DIRECTOR 40.0 0.0 X 138255 0 17833 ZETING WANG SR. DIR OF DIRECT RESPONSE 40.0 0.0 X 129649 0 11408 ALFRED SLANETZ CHAIR OF THE BOARD 5.0 0.0 X X 0 0 0 EDWARD S WEST TREASURER 2.0 0.0 X X 0 0 0 JUDITH P BARNHARD DIRECTOR 1.5 0.0 X 0 0 0 KAREN BURKE DIRECTOR (EFF 02/2022) 1.5 0.0 X 0 0 0 WENDI P DENNARD DIRECTOR (THRU 02/2022) 1.5 0.0 X 0 0 0 BRIAN LEYLAND-JONES DIRECTOR 1.5 0.0 X 0 0 0 LANCE KAWAGUCHI DIRECTOR (EFF 02/2022) 1.5 0.0 X 0 0 0 1137523 0 161555 5 false true false CENVEO WORLDWIDE LIMITED ROUTE 866 PO DRAWER C WILLIAMBURG PA 16693 ENVELOPE PRINTING 451471 AMERGENT INC 9 CENTENNIAL DRIVE PEABODY MA 01960 CONSULTING & MNGT 323810 CALMARK GROUP LLC 6755 SAYRE AVE BEDFORD PARK IL 60638 MAIL SHOP 300719 CP DIRECT INC 4600 A BOSTON WAY LANHAM MD 20706 PRINTING SERVICES 255326 REDFIELD DIRECT LLC 11422 MIRACLE HILLS DR 450 OMAHA NE 68154 LABEL PRINTING 221237 7 35091 131212 8015688 117238 8181991 0 199803 199803 0 2421 2421 0 0 0 395156 456744 -61588 -61588 -61588 0 131212 1267 -1267 -1267 0 0 0 0 0 0 MAILING LIST RENTALS 541800 86699 86699 86699 8408059 226068 2043162 2043162 232017 232017 10000 10000 0 0 726620 549076 172517 5027 0 1198239 893509 139482 165248 106328 80522 8735 17071 51999 34885 10178 6936 111567 83252 17818 10497 0 0 23310 800 22510 0 53172 53172 0 31557 31557 27852 27852 312114 150317 135647 26150 36338 7466 19799 9073 107768 47194 46404 14170 368135 238739 5231 124165 0 230124 171051 37287 21786 71500 13662 53052 4786 0 104000 104000 0 0 14766 10996 2371 1399 26934 20050 4345 2539 DIRECT MAIL PROGRAMS 2482071 1387185 0 1094886 LOCK BOX SERVICE 82815 50493 0 32322 PROCESS FEES-LIST SALES 18294 10956 0 7338 MISCELLANEOUS FUNDRAISING 14226 0 600 13626 8484908 6139332 757000 1588576 X 2826252 1712623 1113629 4550 1162 2206647 1976379 0 0 87021 58323 0 0 0 0 0 0 0 0 196004 483323 226556 197487 35935 29069 5538898 4694792 442 200442 0 0 0 0 4073737 3275588 12143234 10719078 1340119 876435 228483 1285132 135 135 0 0 0 0 0 0 0 0 200000 0 1150621 949794 2919358 3111496 X 5208434 4277731 4015442 3329851 9223876 7607582 12143234 10719078 -76849 -1539445 X false true X true false X 12714798 9898471 10990906 9444496 8181991 51230662 0 0 12714798 9898471 10990906 9444496 8181991 51230662 410189 50820473 308859 270568 222444 276898 202224 1280993 2859 2859 259968 301733 192317 135298 86699 976015 53490529 0.95008 0.94990 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 3040 true true 7190200 2206693 -605813 2585648 6205432 7784738 3290006 213641 4098185 7190200 7915837 3260266 193223 3584588 7784738 10396983 4136982 286710 6904838 7915837 8699102 7119860 -271815 5150164 10396983 0.46700 0.33100 0.20200 false false 26890 14690 12200 154285 143056 11229 45382 39742 5640 29069 AMOUNT HELD IN TRUST BY OTHERS 2427684 RIGHT OF USE ASSET 847904 3275588 0 LEASE LIABILITY 949794 949794 X PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FIN 48 FOOTNOTE: The Foundation has been recognized by the Internal Revenue Service ("IRS") as exempt from income tax under Internal Revenue Code Section 501(c)(3) and related state statutes, except for income tax on unrelated business income, if any. It qualifies as a public charity under Section 509(a)(1). The Darwin Foundation has been recognized by the IRS as exempt from income tax under Section 501 (c)(3) and related state statutes, except for income tax on unrelated business income, if any. It is a supporting organization to NFCR under Section 509(a)(3). NFCR Western Chapter, a California nonprofit corporation, and NFCR Mid-Atlantic Chapter, a District of Columbia nonprofit corporation were added in 2011 by the Foundation to its roster of subordinate organizations covered under the group exemption ruling, dated April 26, 2010, issued by the Internal Revenue Service to the Foundation. Both chapters are exempt from federal and state income tax, except for income tax on unrelated business income, as organizations described under section 501 (c)(3) of the Internal Revenue Code and related state statutes. Accounting principles generally accepted in the United States of America require management to evaluate income tax positions taken and accrue an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has evaluated the income tax positions taken and concluded that as of December 31, 2022 there are no uncertain positions taken or expected to be taken that would require recognition in the consolidated financial statements. The Foundation and affiliates are subject to routine audits by taxing jurisdictions, however, there are currently no audits in progress for any tax periods. In addition, there have been no tax related interest or penalties for the periods presented in these consolidated financial statements. Should such penalties and interest be incurred, the Foundation's policy is to recognize them as general and administrative expenses on the consolidated statements of activities. true Europe (Including Iceland and Greenland) 0 0 Grantmaking 5000 East Asia and the Pacific 0 0 Grantmaking 5000 0 0 0 0 10000 10000 RESEARCH REVIEW Europe (Including Iceland and Greenland) 1 5000 CHECK RESEARCH REVIEW East Asia and the Pacific 1 5000 CHECK false false false false false false PART I, LINE 2 Procedure for monitoring use of grants outside USA: Grant and Contract recipients are required to submit quarterly expenditure reports and annual progress reports to NFCR. X X X X X X X true AMERGENT INC 9 CENTENNIAL DR PEABODY MA 01960 false 3418776 31557 3387219 3418776 31557 3387219 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WY PLAY 4 THE CURE 117443 117443 1256 DC GOLF 6474 6474 0 7295 7295 11 131212 131212 1267 1267 -1267 true CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVENUE CLEVELAND OH 44106 341018992 501(c)(3) 32895 RESEARCH CONTRACTS DANA-FARBER CANCER INSTITUTE 44 BINNEY ST MAIL STOP L229 BOSTON MA 02115 042263040 501(c)(3) 37500 RESEARCH CONTRACTS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(c)(3) 100000 RESEARCH CONTRACTS UNIVERSITY OF CALIFORNIA AT SAN DIEGO PO BOX 12385 LA JOLLA CA 92093 943067788 501(c)(3) 12500 RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 72900 RESEARCH CONTRACTS UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 19104 231352685 501(C)(3) 71728 RESEARCH CONTRACTS AIM HI ACCELERATOR FUND 5515 SECURITY LN 1105 ROCKVILLE MD 20852 824322538 501(C)(3) 1000000 collaboration MASSACHUSETTS GENERAL HOSPITAL P O BOX 414876 BOSTON MA 02241 041564655 501(C)(3) 61852 RESEARCH CONTRACTS OREGON HEALTH AND SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK RD PORTLAND OR 97239 237083114 501(C)(3) 69562 RESEARCH CONTRACTS JOHNS HOPKINS UNIVERSITY 3400 N CHARLES ST BALTIMORE MD 21218 520595110 501(C)(3) 50000 RESEARCH CONTRACTS UNIVERSITY OF WASHINGTON 509 OLIVE WAY SEATTLE WA 98101 916001537 16367 RESEARCH CONTRACTS NEW YORK UNIVERSITY GROSSMAN SCHOOL MEDICINE 1 PARK AVE 6TH FLOOR NEW YORK NY 10016 135562308 501(C)(3) 40158 RESEARCH CONTRACTS UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CTR 660 PARRINGTON OVAL RM 119 NORMAN OK 73019 173601798 12500 RESEARCH CONTRACTS MEMORIAL SLOAN KETTERING CANCER CENTRE 1275 YORK AVE NEW YORK NY 10065 912154267 501(C)(3) 85000 RESEARCH CONTRACTS YALE UNIVERSITY P O BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 260000 RESEARCH CONTRACTS UNIVERSITY OF TX-MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 99999 RESEARCH CONTRACTS THOMAS JEFFERSON UNIVERSITY 1101 MARKET ST PHILADELPHIA PA 19107 231352651 501(C)(3) 7500 RESEARCH CONTRACTS 14 3 CANCER RESEARCH 3 142017 RESEARCH REVIEW 4 60000 AWARDS FOR CANCER RESEARCH PROGRESSION 1 30000 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X X X true false false false false false false true false SUJUAN BA PRESIDENT/CEO 400920 0 25000 0 1188 0 53000 0 31633 0 511741 0 0 0 YI WANG CHIEF STRTGY OFF(THRU 08/2022) 147594 0 0 0 99896 0 17747 0 1008 0 266245 0 0 0 KWOK LEUNG CFO/SECRETARY 185500 0 8333 0 1188 0 27825 0 1101 0 223947 0 0 0 BRIAN WACHTEL EXECUTIVE DIRECTOR 131775 0 6300 0 180 0 15813 0 2020 0 156088 0 0 0 SCHEDULE J, PART I, LINE 4A YI WANG RECEIVED A SEVERANCE PAYMENT OF $98,372. SCHEDULE J, PART I, LINE 7 BONUSES PAID TO KWOK LEUNG, BRIAN WACHTEL, AND ZETING WANG ARE DETERMINED ON AN ANNUAL BASIS BY THE BOARD AND/OR MANAGEMENT OF NFCR. RETENTION BONUS PAID TO SUJUAN BA IS DETERMINED BY THE BOARD ON HER EMPLOYMENT CONTRACT. X 5 117238 stock market value false true false PART III, LINE 1 - ORGANIZATION'S MISSION: The National Foundation for Cancer Research (NFCR) is a leading public charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, cures for cancer. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major funding sources. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. Since 1973, NFCR has provided more than $410 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. NFCR is committed to fighting cancer by funding high-risk, high-impact, and potentially high-reward discoveries in the labs and transforming them into life-saving treatments for cancer patients. Through global collaboration, NFCR is making unique impacts on new, accelerated paths to a cure. NFCR envisions a world without cancer! PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS: HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS -------------------------------------- WITH SUPPORT FROM OUR GENEROUS DONORS, NFCR-FUNDED SCIENTISTS HAVE MADE NUMEROUS REMARKABLE ADVANCES IN THE FIGHT AGAINST CANCER. THEIR RESEARCH ENCOMPASSES A WIDE VARIETY OF FIELDS, MANY OF WHICH COULD ULTIMATELY LEAD TO A CURE FOR THIS DEADLY DISEASE. Pairing Lung Cancer Patients with the Right Treatment: ------------------------------------------------------ LUNG CANCER PATIENTS WITH MUTATIONS IN THE ALK GENE (OR ALK-POSITIVE OR ALK+) EVENTUALLY BECOME RESISTANT TO THE 1ST, 2ND, AND 3RD LINE OF STANDARD THERAPIES WITH NO OTHER AVAILABLE LIFE-SUSTAINING THERAPY. AARON HATA, M.D., PH.D. AND JESSICA LIN, M.D. ARE USING A NEW BREAKTHROUGH TECHNOLOGY THAT IDENTIFIES AND QUANTIFIES THE GENES IN PRESERVED BIOPSY SAMPLES, A METHOD NOT PREVIOUSLY POSSIBLE. A DEEPER UNDERSTANDING OF HOW CANCERS CHANGE WITH TARGETED THERAPIES CAN POTENTIALLY NOMINATE NEW WAYS TO TREAT RESISTANT CANCERS AND SAVE LIVES. Predicting Why Cancer Spreads in Some Patients: ----------------------------------------------- DANNY WELCH, PH.D. AND ISIDORE RIGOUTSOS, PH.D. ARE FINDING VARIABILITIES IN A SHORT FORM OF RNA IN THE CELL PART THAT PRODUCES OUR BODY'S ENERGY, POSSIBLY EXPLAINING WHY CANCER SPREADS IN SOME PATIENTS BUT NOT IN OTHERS. THIS MAY PARTIALLY EXPLAIN RACIAL DISPARITIES IN CANCER RATES AND SEVERITY. THEIR RESEARCH SUGGESTS A SIMPLE BLOOD TEST COULD GUIDE DOCTORS TO AGGRESSIVELY TREAT PATIENTS WHOSE CANCER MAY SPREAD, OR SPARE PATIENTS AT LOW RISK FROM UNDERGOING TREATMENT SIDE EFFECTS. CAR-T Cell Immunotherapy for Pancreatic Cancer: ----------------------------------------------- THERE ARE CURRENTLY NO EFFECTIVE CAR T CELL THERAPIES (OR T CELL-BASED IMMUNOTHERAPIES) FOR PANCREATIC CANCER. AVERY POSEY, PH.D. AND COURTNEY HOUCHEN, M.D. ARE DEVELOPING CAR T CELLS THAT TARGET TWO TUMOR-ASSOCIATED PROTEINS CONTRIBUTING TO IMMUNE SUPPRESSION. THIS APPROACH MAY ENHANCE THE ANTI-TUMOR EFFICACY OF THESE CAR T CELLS AND PREVENT TUMOR ESCAPE. THIS WORK IS IDENTIFYING THE MOST PROMISING CANDIDATES FOR FUTURE CLINICAL STUDIES - GIVING PANCREATIC PATIENTS HOPE FOR A NEW TREATMENT. Progress in Triple-Negative Breast Cancer: ------------------------------------------ LISA COUSSENS, PH.D. AND ELANA FERTIG, PH.D. HAVE TEAMED UP TO TACKLE THE PERSISTENT CHALLENGE OF TRIPLE-NEGATIVE BREAST CANCER (THE MOST DIFFICULT TO-TREAT BREAST CANCER). THEY ARE HOPING TO PREDICT PATIENTS' RESPONSES TO FOUR DIFFERENT THERAPIES GIVEN IN SEQUENCE AND TO UNDERSTAND AHEAD OF TIME IF PATIENTS WILL BE RESISTANT TO THOSE THERAPIES. BY USING ARTIFICIAL INTELLIGENCE APPROACH TO COMBINE DATASETS FROM THE CANCER MODELS WITH THOSE FROM HUMAN CLINICAL TRIALS WILL ENABLE DOCTORS TO IDENTIFY PATIENTS WHO WOULD RESPOND, ALLOWING A MORE GUIDED AND PRECISE DELIVERY OF IMMUNOTHERAPY. Launching New Research Program: Expanding Powerful Detection Technology for Many Cancers: -------------------------------------------------------------------------- - ADVANCED AND METASTATIC CANCER TAKES THE LIVES OF MORE THAN 90% OF PATIENTS. EARLY DETECTION OF CANCER AND ITS PROGRESSION IS A DIRE UNMET NEED FOR PATIENTS, FAMILIES, AND THE CANCER RESEARCH COMMUNITY. NFCR'S NEW INITIATIVE FOCUSES ON CANCER CELL DIAGNOSTIC TECHNOLOGY TO PROVIDE AN INCREASED UNDERSTANDING OF THE LIVE CANCER CELLS OR CIRCULATING TUMOR CELLS (CTCS) IN REAL-TIME AND AN INCLUSIVE UNDERSTANDING OF THE TUMOR MICROENVIRONMENT AT THE CELLULAR, GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC LEVELS. TEN LEADING RESEARCHERS FROM ACROSS THE GLOBE HAVE BEGUN TO GENERATE THE KNOWLEDGE NEEDED TO ACCELERATE THIS MOST CRITICAL CANCER PROBLEM FOR CANCER PATIENTS OF EARLY DETECTION AND MONITORING OF ADVANCED CANCER. Botanical Drug Treating Patients in Clinical Trials: ---------------------------------------------------- Over two decades of funding from NFCR supporters helped Yung-Chi Cheng, Ph.D. and his team develop YIV-906, a botanical drug with multiple anti-cancer properties that enhance immunotherapy and chemotherapy. NFCR's AIM-HI Translational Research Initiative support facilitated the translation of YIV-906 to reach the clinical stages. Now, a global clinical trial is treating liver cancer patients with YIV-906 combined with a frontline drug. Since YIV-906 also protects the gastrointestinal tract from harsh side effects of many therapies, the botanical should alleviate adverse effects of the frontline drug that has caused many patients to discontinue its use. With success in final phase clinical trials, YIV-906 could become the first U.S.-approved botanical cancer drug, a remarkable achievement. Unique Clinical Trial Gives Hope to Brain Cancer Patients: ---------------------------------------------------------- A revolutionary clinical trial model, GBM AGILE, is now available to treat patients with the deadliest brain cancer, glioblastoma (GBM). Patients who have not had a new effective treatment in decades, now have hope for survival. GBM AGILE's unique design surpasses standard trials to efficiently evaluate multiple new drugs and drug combinations simultaneously. Benefits include lower cost, reduced time, and fewer patients required to evaluate potential new therapies. Five experimental therapies are available for "treatment arms" in GBM AGILE. In 2022, more than 40 U.S. cancer centers were open to treat patients in the U.S. and Canada, and Trials expanded into Europe. Since its opening in June 2019, GBM AGILE trial has screened more than 1000 patients into the treatment arms. Enrollment rates are 3 to 4 times greater than traditional GBM studies. NFCR has been a pioneer and founding supporter of GBM AGILE. We are also a strategic partner of the Global Coalition for Adaptive Research (GCAR), the official nonprofit sponsor of GBM AGILE. This uniquely designed clinical trial platform is now being utilized to rapidly test new treatments for COVID-19 and ovarian cancer and in the future for other cancers. New Treatment for Childhood Cancer: ---------------------------------- Lack of therapies made specifically for young patients forces pediatric oncologists to use adult cancer drugs. In addition to debilitating side effects that can last a lifetime, there are many forms of childhood cancer whose outlook is poor. Unfortunately, financial investment to develop specific pediatric cancer drugs has been dismal. NFCR's AIM-HI Translational Research Initiative supports a pipeline to develop treatments for the most common pediatric cancers with the worst outcome. Volasertib is the pipeline's first drug and will soon reach clinical trials to treat rhabdomyosarcoma, a rare and deadly childhood cancer affecting 450 new patients yearly. Volasertib has the FDA Rare Pediatric Disease Designation to fast-track the drug approval process. Volasertib also has from the FDA Orphan Drug Designation (for diseases that affect less than 200,000 individuals) that provides tax credits to reduce clinical trial costs and a waiver of new drug application fees - saving developers of volasertib nearly $2.9 million dollars. These benefits will save precious time and money for patients, doctors and drug developers. Your commitment to funding this unmet medical need for better treatments is making a difference in the lives of children! NFCR'S CANCER PATIENT TREATMENT ASSISTANCE: ------------------------------------------- A cancer diagnosis comes with panic, confusion, uncertainty and many questions: what tests should be scheduled, what are the best treatment options, and are there clinical trials for a new therapy that are suitable to the patient's cancer. NFCR understands the patient's frustrations and needs, and we provide assistance through the difficult time by linking a person in need with the Cancer Patient Treatment Assistance, where one may receive expert professional help from our oncologists. . Understanding the diagnosis and treatment options . Recommend top oncologists to meet specific needs and coordinate the referral process . Identify clinical trials of the newest therapies for advanced cancer or rare tumors for which no standard care or effective therapy is available This medical advice is provided as a resource for patients to consult with their medical team. PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: NFCR provides the public with free materials containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message has been mailed annually to households, reaching over 266,000 email subscribers and tens of thousands of individuals through our social media channels (Twitter and Facebook) and through our website and blogs, helps to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. PART IX, LINE 26, JOINT COSTS ALLOCATION: NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 50 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY POSTAL MAIL, EMAIL, PHONE, WEBSITE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT ABOUT CANCER AND UPHOLD ITS MISSION, AND AT THE SAME TIME TO PROVIDE FUNDRAISING OPPORTUNITIES. THE COSTS RELATED TO THESE JOINT ACTIVITIES ARE ALLOCATED, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. DARWIN FOUNDATION 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 371473821 CANCER RSRCH DC 501(C)3 509(A)(3) NFCR true RESEARCH FOR A CURE 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 010744146 CANCER RSRCH DC 501(C)3 509(A)(3) NFCR true false false false false false false false false false false false false false false false false false false false